Initially, CFTR genotyping was done in individuals with clear phenotypic manifestations of CF who demonstrated CFTR dysfunction through sweat chloride measurement. Therefore, if a mutation was detected in the CFTR gene in a sample from an individual with CF, it was presumed to be CF-causing. This was accurate for most well-recognized mutations (such as c.1521_1523delCTT [legacy: F508del], c.1652G > A [legacy: G551D], or c.1624G > T [legacy: G542X]), but several important examples were recognized in which variants identified in CFTR were not independently causal of CF. 6, 7 Also, the number of variants in CFTR expanded rapidly as genetic analysis was performed on more patients with CF and in the general population. To address the need for the annotation of CFTR variants, the US CF Foundation assembled an international research group tasked with defining criteria for disease liability and annotating the mutations seen in patients with CF entered in registries. This research group, the clinical and functional translation of CFTR (CFTR2) team, has made an important contribution and has better informed genetic analysis as a part of CF diagnosis.
In this report, we outline the use of CFTR genetic analysis in the diagnosis of CF and other related conditions. The interpretation of CFTR genotyping will focus on the categories of mutations as described by the CFTR2 team. The CFTR2 analysis is a comprehensive annotation of mutations among patients with CF, but there are several important instances in which genetic analysis does not allow a definitive CF diagnosis, or in which information other than CFTR2 should be considered. For example, the use of genetic criteria in diagnosis is insufficient for mutations that are known to be associated with CF in some individuals but no phenotype in others, and for the many mutations not yet characterized by CFTR2. Therefore, the diagnostic challenge of difficult-to-interpret genotypes will remain.
Mutation Annotation
The initial repository for CFTR variants, termed the CF Mutation Database (CFMD), 8 began in 1990, shortly after the CFTR gene was identified. The CFMD content was assembled through voluntary contributions from research laboratories, genetic testing facilities, and clinicians. It is a comprehensive collection of variation in the CFTR gene, with graphic and text search features that incorporate both legacymutation naming, as well as more recent naming rules that are consistent across the genetic community 9,10 (Appendix; available at www.jpeds.com). The database in some cases contains phenotypic information that was included with the submission. For example, it may report that a given mutation was noticed in an individual with infertility. Although this information might be helpful for rare mutations, these single cases do not always reflect the true disease liability of the mutations. The first reported case of a mutation may be the only one noted, even if subsequent occurrences of the mutations have differing phenotypes. Therefore, assessing the disease liability of CFTR variants based solely on whatever data have been submitted to CFMD is of limited usefulness toward CF diagnosis.
Although the CFMD constitutes an excellent existing repository of information on nucleotide variation in the CFTR gene, it was clear that a new approach was essential to comprehensively and consistently address the phenotypic and functional implications of CFTR variants. The CFTR2 project has assembled data from national registries of patients with CF, as well as large clinical databases from countries without a national registry, to collect, quantify, and describe the mutations reported in individuals with CF. 11 These registries and datasets are largely from Europe, North America, and Australia, but also contain representation from the Middle East, Asia, and South America. The mutations seen among this group of individuals with CF can be ranked by frequency to prioritize the analysis and annotation of mutations seen most commonly. Mutations are categorized as CF-causing if they meet clinical, functional, and population/penetrance criteria ( Table I) . Mutations are categorized as mutations of varying clinical consequence (MVCC) if they do not meet clinical and/or function criteria. Categorizing a mutation as non-CF-causing 20 †Not all mutations that cause premature terminations will result in nonsense-mediated decay and no protein (ie, those with terminations in the last exon); in which case, laboratory-based functional analysis is required.
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requires a different approach. Clinical criteria are not considered because it is likely that the patients' phenotypes result from an unidentified variant. Instead, characterization of non-CFcausing requires functional analysis and strong evidence from the general population that these variants are not fully penetrant for CF (that is, they do not result in CF when present in trans with a CF-causing mutation). A fourth category listed in Table I is unknown; the CFTR2 annotation project is ongoing, and analysis has not been completed for all CFTR variants, particularly those that occur at extremely low frequency.
Assigning mutations to these categories of disease liability has the benefit of simplifying genetic interpretation. It is consistent with current recommended practices for variant annotation by the American College of Medical Genetics, while keeping specificity toward the mutations' likelihood of causing CF (as opposed to any phenotype, which may not meet the definition of CF). 12 The following potential shortcomings of this classification hierarchy deserve consideration because they elucidate scenarios in which CFTR molecular genetic analysis may be less helpful in making a CF diagnosis or cases where the context of additional research may be needed.
The Penetrance of Variants Classified as Varying Consequence May Differ
For example, the variant c.3454G > C (legacy: D1152H) is well known to be associated with milder CF disease in some cases. [13] [14] [15] In comparison, the variant c.[350G > A;1210 − 12 [7] ] (legacy: R117H;7T) also is associated with milder disease but has been shown to have many more individuals that possess this variant with a CF-causing variant who do not have disease. 16 
There Is No Special Designation for Mutations Primarily Associated with CFTR-Related Disorders
The recognition of individuals with CFTR mutations and a CFTR-related phenotype who do not meet the diagnostic criteria for CF has led to the definition of CFTR-related disorders. 17 These individuals may have isolated male infertility, recurrent pancreatitis, or bronchiectasis. There are CFTR variants that more frequently (but not exclusively) result in these milder phenotypes. 18, 19 In CFTR2, these variants have been classified as either MVCC or non-CF-causing. Prior reviews of the use of genetics in CF have assigned mutations to categories in a similar fashion as CFTR2 but include a category of mutations leading to CFTR-related disorders. 21, 22 However, the authors of those reviews concede that many of the mutations assigned in the CFTR-related disorder category may also be included in another category. CFTR2 is focused more specifically on individuals with CF, and defining the disease liability relative to CF.
CFTR2 Is Not Comprehensive
Although the CFTR2 project is a comprehensive systematic annotation of disease liability, there is a great deal of published literature on mutations not yet included in CFTR2. This may occur for populations under-represented in CFTR2. Other research may be of considerable help, especially for mutations reported as "unknown" by CFTR2.
Penetrance
The genetic term "penetrance" refers to the proportion of people with a given genotype who will exhibit symptoms of a condition. For CF, this can be defined as the proportion of people with a specific mutation combination, (specifically, the individual mutation under analysis plus any known CF-causing mutation on the other allele) who will satisfy the diagnostic criteria for CF. Mutations or genotypes that always lead to CF are said to be 100% penetrant. The most common example of a mutation with 100% penetrance is F508del; this means that every person with the genotype F508del/F508del is expected to have CF. Other mutations, such as the more variable D1152H, are less than 100% penetrant for CF because not all people with this mutation, even in combination with a CFcausing mutation like F508del, will have CF. In this respect, a given mutation is expected to have different penetrance for CF-vs CFTR-related disorders.
Assessing penetrance requires an understanding of the frequency of individuals who have a given genotype but do not have CF (and are, therefore, not represented in CFTR2). There has been great progress in public repositories of genetic variation, which allows better estimates of the allele frequency of a given variant in general (presumably healthy and unaffected) populations. As part of the penetrance analysis for the CFTR2 assignment of disease liability, the allele frequency in individuals with CF is compared with the allele frequency in the general population as estimated using data from the 1000 genomes browser. 23, 24 Mutations such as G551D are more common among individuals with CF. Therefore, the relative prevalence of patients with CF with this mutation can be accurately estimated by applying the Hardy-Weinberg principle to the allele frequency in European populations. For mutations such as c.2991G > C (legacy: L997F), the allele frequency in the general population is much higher than among individuals with CF. This suggests that many individuals carry this allele, in trans with a CF-causing allele, are not entered into registries of patients with CF, and are, therefore, not reflected in CFTR2. However, this comparison of the general to the population with CF does not include individuals who may have phenotype (such as infertility) because of L997F but are not entered into a registry of patients with CF.
Use of Genetics in CF Diagnosis
The US Cystic Fibrosis Foundation 2015 Diagnosis Consensus Committee voted to adopt the guidelines shown in Table II regarding the use of molecular genetic tests to aid in demonstrating CF diagnosis.
specific CFTR mutations. Genotyping errors are more likely to occur in NBS (state-run laboratories doing a large number of tests) than in genetic testing done for clinical purposes. Therefore, depending on the laboratories' quality metrics, repeat genotyping may be indicated to confirm the genotype identified through NBS.
In the event that an individual being considered for CF has a genotype that is not annotated by CFTR2, other literature should be consulted. If other research is lacking or equivocal, the clinician will need to rely more heavily on other tests to demonstrate CFTR dysfunction, such as sweat chloride testing or physiologic CFTR testing through nasal potential difference or intestinal current measures. Some specific genotype combinations and recommendations are described in Table III .
Genetic Tests for CFTR
As the use of genetic testing in medical practice has expanded, testing for more variation has become less expensive. Traditionally, testing for CFTR mutations was done by panel tests that detect a given number of mutations (usually 5-150 mutations). These panels can be customized to better detect local variants seen in the local populations. Sequencing is a comprehensive check of all nucleotides in the coding region of the gene and typically also includes noncoding regions where known mutations exist. Sequencing now is increasingly performed using "next-gen" technology. One application of this technology involves only reporting mutations with well-established disease liability as abnormal in the initial screening report, but with the ability to "go back" and reveal variants of uncertain disease liability if the clinician believes the clinical scenario warrants this. 27 Sequencing is more sensitive, but may not detect mutations in the noncoding region and also may not detect large deletions or duplications in the gene. Deletions and duplications can specifically be tested for by separate tests such as multiplex ligation-dependent probe amplification. Deletions and duplications may be detected by certain next-gen platforms, but this practice will vary by testing laboratory. 28 
Table II. 2015 CF Foundation diagnosis consensus conference recommendations for diagnosis of CF using CFTR2
Statement numbers
Consensus statements
11
The latest classifications identified in the CFTR2 project 25 should be used to aid with CF diagnosis: • CF-causing mutation: individuals with 2 copies on separate alleles will likely have CF (clinical sweat confirmation needed) • Mutation of varying clinical consequence (MVCC): a mutation that in combination with a CF-causing mutation or another MVCC mutation may result in CF • Uncharacterized mutation/mutation of UNK: mutation that has not been evaluated by CFTR2 and may be disease causing or of variable clinical consequence or benign • Non-CF-causing mutation: individuals with 1 or more are unlikely to have CF (as a result of that allele) 12 In individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, the identification of 2 CF-causing mutations (defined by CFTR2) is consistent with a diagnosis of CF. Sweat chloride testing is necessary, though, to confirm the diagnosis. 13 The absence of detection of 2 CF-causing CFTR mutations does not exclude a diagnosis of CF.
Table III. Effects on diagnosis recommendations of different categories of CFTR mutations in the presence of a CFcausing mutation (in trans)
CFTR genotype
Recommendations for interpretation Allele 1
Allele 2
CF-causing mutation
Variant not characterized by CFTR2 (or categorized as "unknown")
This category includes mutations not annotated by CFTR2. Therefore, this genotype may or may not result in CF, depending on the disease liability of the uncharacterized variant. In some cases, there may be existing literature on the variant. If so, the same criteria used by CFTR2 can be used to define the pathologic potential for that variant.
The literature on the variant should include clinical evidence (described in well-phenotyped patients with CF), functional evidence (either predicted to result in no protein, tested for RNA or protein levels, or tested for chloride conductance), and finally, population evidence. The population evidence can be investigated by looking for the variant in public databases such as 1000 genomes 23 or the Exome Aggregator Consortium. 26 A high allele frequency of the variant in these public databases would suggest that it is not fully penetrant.
Mutation of varying clinical consequence
The likelihood that this genotype will result in CF will depend on the penetrance of the mutation with varying clinical consequence. In most cases, that is not well known. The clinical scenario becomes the key determinate of the diagnostic label. This can become challenging, especially if this genotype is detected in a newborn (eg, Extended Genetic Testing as Part of NBS in California). Because lung and pancreatic phenotypes progress over time, a clinical scenario that meets CF criteria may not occur until later in life.
No variant identified
The key to interpreting a result in which only one variant identified is evaluating the extent of genetic testing. If only a panel containing common mutations was used, there may be an unidentified mutation. If there is suspicion from either clinical criteria or from CFTR physiologic testing, extended CFTR analysis should be performed. Sequencing and deletion duplication testing have a very high negative predictive value, but cannot completely exclude the CF.
Non-CF-causing
The non-CF-causing mutations in CFTR2 were all identified in patients believed to have CF (enough to be entered in a registry). This occurred because the individual: (1) does not actually have CF, and the diagnosis is incorrect; (2) has mild organ system manifestations that do not typically meet diagnostic criteria for CF, but may be an example of a CFTR-related disorder; or (3) has CF, but 1 of the causative variants has not been identified (and the non-CFcausing variant is inappropriately assumed the culprit). This (2 mutations on the same chromosome) would be an example of a complex allele.
Complex alleles, in which multiple variants are present on the same chromosome, present an added diagnostic challenge. In some cases, disease liability is well recognized, but this is not often the case. For the mutation c.350G > A (legacy: R117H), it is well established that differing intron 9 (legacy intron 8) modifiers affect the severity and penetrance of this allele. 6, 29 Another example of a complex allele is one containing the common variant L997F. Individuals who carry this and c.350G > T (legacy: R117L) on the same allele have a more severe phenotype than those carrying just L997F alone. 30 When multiple mutations are detected and there is suspicion of a complex allele, testing of the parents or siblings is needed to determine which variants are inherited together.
In general, genetic tests designed to identify the presence of one of a defined panel of CFTR mutations can be designed to be highly specific as they test for only CFTR variants that are known to cause CF. The sensitivities of these panels depend on how well the selected variants reflect the population being tested. Sequencing (and deletion/duplication testing) increases the sensitivity of the assay, but it is less specific because it may identify a CFTR variant that is uncharacterized or one that is known to be associated with varying clinical consequences. No genetic testing is completely infallible, and clinical suspicion should always take precedence.
Example: Extended Genetic Testing as Part of NBS in California
Because of the racial diversity in California, traditional NBS algorithms that rely on standardized panels of CFTR mutations were not sensitive enough to meet state NBS standards. In 2007, California initiated a CF NBS program that uses a 3-tiered approach: (1) a high immunoreactive trypsinogen level in a newborn's dried bloodspot; (2) which triggers use of a panel of 40 mutations selected from the mutations found in local CF clinics; (3) and then CFTR sequencing is performed for newborns with only 1 mutation identified from the California panel. 31 A consequence of this approach has been the detection of MVCC and (especially in the Hispanic community) previously unrecognized CFTR mutations that have not yet been classified. 32 Thus, the program has identified large numbers of infants with a positive newborn screen who do not fulfill current diagnostic criteria for CF, and who have mutations with as-yet-unknown likelihood of causing disease.
Of the 2 124 050 infants screened in the period from 2004 to 2011, 174 infants were diagnosed with CF on the basis of 2 panel mutations. Another 674 infants displayed 1 California panel mutation, with a second mutation found through CFTR sequencing. In 98 of these individuals, the genotype was determined to be non-CF-causing. In follow-up, these infants had no signs or symptoms related to CF, and none of them presented with high sweat chlorides or pancreatic insufficiency by 2 to 6 years of age. 33 In 60 infants, the mutation identified by sequencing was known to be CF-causing, and these individuals were diagnosed with CF. The remaining infants were grouped for further study according to the predicted effects of the second mutation: MVCC (n = 78), mutations of unknown significance (UNK; n = 244), and intron 9 5T variants (splicing efficiency mutation, n = 194).
In 2-4 years of follow-up, a small but significant percentage of children from the MVCC (4/78, 5%) and UNK (27/ 244, 11%) groups had been diagnosed with CF because of either having sweat chloride level ≥60 mmol/L or developing pancreatic insufficiency. These data highlight the challenge of uncharacterized mutations in screening: some unknown or uncharacterized mutations may cause CF, and others have evidence of being benign. The 5T variants are under analysis.
These outcomes highlight the potential benefit and challenges of using CFTR sequencing in NBS, which has expanded knowledge of CFTR variants in populations in which CF is uncommon but under-recognized. Sequencing will identify mutations that have no disease annotation or are associated with varying clinical consequences (MVCC). When used in screening, this will result in large numbers of patients with CRMS/CFSPID (Another article in the Supplement provides additional information on this topic. 34 ) Because some children may develop different CF symptoms over the course of their lifetime, this presents the opportunity to detect disease before it occurs. However, the added sensitivity is countered by the distinct challenges resulting from the greater need for CF clinics to follow more children, and the potential consequences of over-labeling or "medicalizing" these asymptomatic children is not known. Because the prognosis for children in the MVCC and UNK groups described above is still not clear, further study is needed to better recognize features that will predict disease (or lack thereof) over the lifetime. Until this is done, sequencing is not a universal solution to establishing a CF diagnosis.
Discussion
The majority of individuals with CF can be diagnosed readily with sweat testing and with CFTR genetic analysis showing wellrecognized CF-causing mutations. Genetic analysis can be difficult to interpret if mutations identified are rare and uncharacterized or are known to be associated with varying clinical consequences. The CFTR2 project has characterized mutations using clinical, functional, and population/penetrance criteria. Although in the final analysis the clinician's judgment must prevail, the genotypic information provided to the clinician is increasingly helpful, both in making the diagnosis and in choice of life-changing therapies that are becoming available for many individuals with CF. ■
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